Rick Doblin (b. 1953)
American psychedelic policy advocate, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS), and the person most responsible for building the institutional infrastructure — decades of clinical trials, philanthropic funding, and regulatory patience — that made a 2024 FDA drug application for MDMA-assisted therapy possible in the first place. His story is also, more recently, a cautionary one about what happens when advocacy and science get too entangled with each other.
Born November 30, 1953, in Chicago and raised in Skokie, Illinois, Doblin’s path to founding the field’s most influential advocacy organization was unusually long and personal. After withdrawing from New College of Florida in 1971, he eventually completed a psychology degree there in 1987, then pursued a Ph.D. in public policy at Harvard’s Kennedy School of Government, completed in 2001 with a dissertation on the regulation of medical psychedelics and marijuana. By then, MAPS itself was already fifteen years old.
Building MAPS
Doblin founded MAPS in 1986, in direct response to the federal government’s decision that year to place MDMA into Schedule I — the same emergency scheduling that shut down the substance’s brief, promising run as an adjunct to psychotherapy. His strategy was patient and, at the time, almost eccentric: rather than fighting prohibition directly, MAPS would work the FDA’s own drug approval pathway from the inside, running the same rigorous phases of clinical trials any pharmaceutical company would need, on the theory that mainstream medical approval for one psychedelic compound could open the door for the rest of the field behind it.
It worked, for a long time, remarkably well. Over roughly four decades, MAPS raised more than $150 million, trained over 500 therapists, ran the world’s largest psychedelic science conference, published more than 23 peer-reviewed studies, and eventually generated the clinical data behind the first-ever new drug application submitted to the FDA for a classical psychedelic-assisted therapy — MDMA, for post-traumatic stress disorder, spun out into a public benefit corporation called Lykos Therapeutics.
The 2024 setback
That effort hit a serious wall in June 2024, when an FDA advisory panel voted against recommending approval, citing concerns about unblinded trial design (nearly impossible to avoid with a drug whose effects are obvious to both patient and therapist), incomplete adverse-event reporting, and a reliance on therapists trained internally by MAPS itself rather than independently. The fallout was severe: Lykos cut roughly 75% of its workforce that August, and the journal Psychopharmacology retracted three MAPS-affiliated papers over integrity concerns, including undisclosed prior knowledge of a serious therapist misconduct case.
That case — involving a 2015 MAPS-sponsored trial participant, Meaghan Buisson, who reported unethical conduct and boundary violations by two of her session therapists — had first been formally raised with MAPS in 2018, and the organization did not sever ties with the therapists involved or fully act on it until 2019, drawing criticism for the delay and for the broader question it raised: whether an organization built as much around advocacy as around science could police its own trials with the independence the FDA ultimately said it lacked. At the same 2024 hearing, one academic critic went further still, describing the dynamics around Doblin’s own long-stated vision — of psychedelics eventually producing a kind of “spiritualized humanity” through widely shared mystical experience — as resembling a “therapy cult.”
Where things stand now
Doblin stepped back from day-to-day leadership in January 2023, moving from executive director to president, and MAPS is now led by co-executive directors Betty Aldworth and Ismail Lourido Ali. Marking the organization’s 40th anniversary in 2026, Doblin struck a notably more sober tone than his earlier decades of advocacy: “We are closer than ever to psychedelics becoming legal medicines again, but what’s emerging looks different from what I spent 40 years fighting for” — voicing concern less about whether legalization happens than about whether the therapeutic substance of the work survives being commercialized, and whether access ends up equitable rather than concentrated.
Sources: